FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
FDA批准摘要:尼拉帕尼联合醋酸阿比特龙固定剂量组合用于治疗BRCA突变转移性去势抵抗性前列腺癌
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-0883
Maguire, William F; Chi, Dow-Chung; Agrawal, Sundeep; Joeng, Hee-Koung; Kim-McOlash, Sarah; Manheng, Wimolnut; Bulatao, Ilynn; Sanchez-Solana, Beatriz; Pathak, Anand; Lee, Alice; Han, Yu; Ricks, Tiffany K; Hamed, Salaheldin S; Fiero, Mallorie H; Pierce, William F; Kalavar, Shyam; Ghosh, Soma; Leighton, John K; Tang, Shenghui; Amiri-Kordestani, Laleh; Kluetz, Paul G; Suzman, Daniel L